Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 3, 2010
Date:10/28/2010

ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the third quarter of 2010, on Wednesday, November 3, 2010, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Wednesday, November 3, 2010.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.The teleconference dial-in numbers are as follows:Domestic callers 1-866-730-5768International callers 1-857-350-1592Participant Passcode 11659354The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 3, 2010, beginning at 1:00 PM ET and will be accessible until Wednesday, November 10, 2010, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 14475834.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CONTACT: Cristina Murphy, Communications Manager of Vanda Pharmaceuticals Inc., +1-240-599-4500


'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
2. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
3. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
4. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
5. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. Vanda Presents Phase III Iloperidone Efficacy Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... KEY FINDINGS Patient warming ... reducing loss of blood during surgeries, lowering the ... recovery after surgeries, and decreasing risks of SSIs. ... convective warming system, surface warming systems, and intravascular ... stay at hospitals thus, lowering the healthcare costs ...
(Date:12/7/2016)... 7, 2016 Global Hospital Linen Supply and ... global hospital linen supply and management services market presents ... a global and regional level. The study provides historic ... between 2015 and 2024 based on revenue (US$ Bn). ... market along with their impact on demand during the ...
(Date:12/7/2016)... N.J. , Dec. 7, 2016  Palatin ... it has closed on a previously disclosed underwritten ... $16,500,000.  Canaccord Genuity acted as sole book-running manager, ... Chardan Capital Markets acted as co-manager for the ... approximately $15.4 million in net proceeds, allowing us ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... promoting to the US market its advanced highly customizable contact technology solutions. , ... TURNTAC®. These advanced technologies are ideal for a wide range of applications that ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers ... to residents in the Sacramento/Folsom region, is initiating a charity event to raise ... Another Choice Another Chance treatment center in Sacramento works to provide area teens ...
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
Breaking Medicine News(10 mins):